Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. ...
Twist Bioscience Corporation, listed on NASDAQ under the ticker TWST, is a leading synthetic biology company headquartered in South San Francisco, California. Founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck, the company went public in 2018 and has since grown to employ approximately 948 people. Twist's core ...Twist Bioscience Corporation, listed on NASDAQ under the ticker TWST, is a leading synthetic biology company headquartered in South San Francisco, California. Founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck, the company went public in 2018 and has since grown to employ approximately 948 people. Twist's core innovation lies in its proprietary semiconductor-based manufacturing process that synthesizes DNA on silicon chips, enabling high-throughput, cost-effective production. This platform allows the company to 'write' DNA at a scale previously unattainable, driving applications across multiple sectors. The company's product portfolio includes custom synthetic genes, targeted sequencing panels, exome capture tools, CRISPR libraries, and antibody libraries for therapeutic antibody discovery. These products serve customers in the pharmaceutical, biotechnology, diagnostic, and academic research communities. Twist has established strategic collaborations with organizations such as Boehringer Ingelheim, Kyowa Kirin, and Centogene to apply its technologies in drug development and diagnostics. Financially, Twist has been investing heavily in growth, with a market capitalization of over $7 billion and revenue per share of $6.92 in the trailing twelve months. However, the company is not yet profitable, with a net profit margin of -31.7%, reflecting heavy R&D and scale-up investments. Despite this, Twist's gross profit margin stands at 52%, indicating a strong underlying business model. Key executives include CEO Emily Leproust, President and COO Patrick Finn, and CFO Adam Laponis. Under Leproust's leadership, Twist aims to continue expanding its DNA synthesis capabilities, move into new markets such as DNA data storage, and achieve profitability in the coming years. The company's mission is to make the engineering of biology routine, enabling innovations in medicine, agriculture, and data storage.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$376.6M
+20.3%
+6.9%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-77.7M
+62.8%
+20.4%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
+50.7%
+19.0%
+2.3%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
-36.2%
+48.7%
+12.2%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
-20.6%
+69.1%
+25.5%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-75.6M
-9.3%
+66.5%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
-20.1%
+9.1%
+68.7%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
29.0%
+61.4%
-0.3%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
3.64x
-25.4%
-0.9%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
Operator: Welcome to Twist Bioscience's 2026 Third Quarter Financial Results Conference Call. [Operator Instructions] Please note, this call is being recorded. I would now like to turn the call over to Angela Bitting, SVP of Corporate Affairs. Please go ahead.
Angela Bitting: Thank you, operator. Good morning, everyone. I'd like to thank you for joining us for Twist Bioscience's Conference Call to review our fiscal 2026 third quarter financial results and business progress. We issued our financial results press release before the market, and it is available at our website at www.twistbioscience.com. With me on the call today are Dr. Emily Leproust, CEO and Co-Founder of Twist; Adam Laponis, CFO of Twist; and Dr. Patrick Finn, President and COO of Twist. Today, we will discuss our business progress, financial and operational performance as well as growth opportunities. We'll then open the call for questions. We ask that you limit your questions to only one and then requeue as a courtesy to others on the call. This call is being recorded, and the audio portion will be archived in the Investors section of our website and will be available for 2 weeks. During today's presentation, we will make forward-looking statements within the meaning of the U.S. federal securities laws. Forward-looking statements generally relate to future events or future financial or operating performance. Our expectations and beliefs regarding these matters may not materialize, and actual results in financial periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected. These risks include those set forth in the press release we issued earlier today as well as those more fully described in our filings with the Securities and Exchange Commission. The forward-looking statements in this presentation are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law. We'll also discuss adjusted EBITDA, a financial measure that does not conform with generally accepted accounting principles. Information may be calculated differently than similar non-GAAP data presented by other companies. When reported, a reconciliation between GAAP and non-GAAP financial measures will be included in our earnings documents, which can be found on the Investors section of our website. With that, I will now turn the call over to our CEO and Co-Founder, Emily Leproust.
Emily Leproust: Thank you, Angela, and good morning, everyone. On Slide 3, you will see that this morning, we reported our 14th quarter of consistent growth with record revenue of $118.4 million, growth of 23% year-over-year. This growth reflects the diligence and execution we have employed over the last several years, building for opportunities we see ahead. Sometimes those opportunities are clearly visible many years in advance and others require us to be nimble and engage with our …
